In Vitro Evaluation of Limosilactobacillus fermentum Antagonistic Ability against MDR Pseudomonas aeruginosa Associated with Burn Wound Infection

Abstract

As the interest grows in bacteria that populate the human body rather than merely those that infect it, research is attempting to manage the microbiome in a specific niche to promote human health. Probiotics has experienced significant growth as a result of this utilization of beneficial bacteria. The aim of the study that several isolates of Lactobacillus were examined in order to use it as a probiotic for treating Pseudomonas aeruginosa associated with burn infections. Thirty-six Lactobacillus isolates were collected from different sources and subjected to a screening program to evaluate their antagonism activities against MDR P. aeruginosa that collected from patient with burn infection. Based on results, the isolate Lactobacillus HLB12 showed a highest bacteriocin production which was further characterized as Limosilactobacillus fermentum through 16s ribosomal RNA. Several tests were performed to study the properties of L. fermentum HLB12, in particular its biosafety and suitability to be a successful probiotic. Results showed that L. fermentum HLB12 was resistance to β-lactams group such as Ticarcillin/Cavulnate whereas, it was sensitive to Amikacin, Ciprofloxacin, Levofloxacin. Moreover, results confirmed that L. fermentum HLB12 was safe as probiotic without any health impacts because it has no haemolytic activity. Furthermore, results revealed that this bacterium was strongly adherent and good biofilm producer; had high auto-aggregation capability and high ability of adhering with P. aeruginosa. It was concluded showed a highly antagonistic activity against P. aeruginosa which supported the idea of using L. fermentum as a probiotic that can be used as an alternative for the treatment with antibiotics.